Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.50 (1.20%)
Spread: 2.00 (4.878%)
Open: 41.50
High: 42.00
Low: 41.50
Prev. Close: 41.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Oct 2019 10:37

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Read more
26 Sep 2019 16:33

DIRECTOR DEALINGS: Cambridge Cognition Boss Matthew Stork Buys Shares

DIRECTOR DEALINGS: Cambridge Cognition Boss Matthew Stork Buys Shares

Read more
23 Sep 2019 17:13

DIRECTOR DEALINGS: Cambridge Cognition Non-Executive Chair Buys Shares

DIRECTOR DEALINGS: Cambridge Cognition Non-Executive Chair Buys Shares

Read more
19 Sep 2019 11:52

Cambridge Cognition Interim Revenue Falls As Clinical Trial Sales Lag

(Alliance News) - Neuroscience technology company Cambridge Cognition Holdings PLC on Thursday reported a fall in interim revenue in line with previous guidance that sales were lower than the six

Read more
12 Sep 2019 16:21

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 13 September  JD WetherspoonFull Year ResultsSthreeQ3 Enterprise Investment

Read more
27 Aug 2019 10:28

WINNERS & LOSERS SUMMARY: Carpetright Up After Shareholder Helps Out

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - LOSERS----------Ferguson,

Read more
27 Aug 2019 09:35

Cambridge Cognition Shares Plunge 40% On Increased Loss Guidance

(Alliance News) - Shares in Cambridge Cognition Holdings PLC collapsed Tuesday after the company said it expects to report its loss widened in the first half due to "difficult" trading a

Read more
27 Aug 2019 09:17

Cambridge Cognition shares tumble after profit warning

(Sharecast News) - Digital solutions developer Cambridge Cognition warned on Tuesday that interim losses looked set to widen after revenues dwindled and costs grew in the six months ended 30 June.

Read more
19 Jul 2019 10:37

Cambridge Cognition Inks NeuroVocalix Deal With Pharma Firm

(Alliance News) - Neuroscience technology company Cambridge Cognition Holdings PLC said it has secured a second commercial partnership with an undisclosed pharmaceutical company for its in the at

Read more
1 Jul 2019 15:48

Cambridge Cognition Names Vertual Boss Debra Leeves As Non-Executive

(Alliance News) - Cambridge Cognition Holdings PLC on Monday said it appointed Debra Leeves as a non-executive director with immediate effect.The neuroscience technology company said Leeves

Read more
25 Apr 2019 14:13

Cambridge Cognition To Shuffle Leadership Team At AGM

LONDON (Alliance News) - Neuroscience firm Cambridge Cognition Holdings PLC on Thursday announced a change of leadership at its upcoming annual general meeting.Cambridge Cognition's be

Read more
19 Mar 2019 11:20

Cambridge Cognition wins biggest digital health contract to date

(Sharecast News) - Neuroscience technology company Cambridge Cognition Holdings announced a "significant" new contract on Tuesday, providing its digital health technologies to a major pharmaceutical company for application in a clinical stage development programme.

Read more
14 Mar 2019 14:03

Lombard Odier Asset Management Holds 5.8% Cambridge Cognition Stake (ALLISS)

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Thursday that Lombard Odier Asset Management Europe Ltd holds a 5.75% stake in the cognitive assessment software firm after a on the

Read more
7 Mar 2019 12:32

Cambridge Cognition slips as low order intake sends loss deeper

(Sharecast News) - Cambridge Cognition's shares slipped on Thursday after it reported that low order intake from 2017 had caused its annual losses to widen and revenues to fall.

Read more
31 Jan 2019 13:28

Cambridge Cognition soars on Indian software partnership

(Sharecast News) - Cambridge Cognition leapt on Thursday after entering a partnership with a major pharmaceutical company to deliver online neurological testing to patients in India using its cloud-based CANTAB Connect platform.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.